Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Dermatologic 1

Conditions

Uveal Melanoma 2Melanoma 2Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Breast Neoplasms 1

Interventions

pembrolizumab 21Cyclophosphamide 18fludarabine 8Radiotherapy 8Radiosurgery 7Nivolumab 7poly ICLC 6fludarabine phosphate 6aldesleukin 6Therapeutics 6Paclitaxel 6Magnetic Resonance Spectroscopy 6durvalumab 5Psychiatric Rehabilitation 5Interleukin-2 5Drug Therapy 5Docetaxel 5Cisplatin 5temsirolimus 4cemiplimab 4Trastuzumab 4Temozolomide 4Sirolimus 4Gemcitabine 4Flow Cytometry 4Filgrastim 4Carboplatin 4tremelimumab 3technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 3pazopanib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × CR011-vcMMAE × Dermatologic × Clear all
NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡